Status:

COMPLETED

Trial of Resistance and Endurance Exercise in Amyotrophic Lateral Sclerosis (ALS)

Lead Sponsor:

Johns Hopkins University

Collaborating Sponsors:

ALS Association

Conditions:

Amyotrophic Lateral Sclerosis

Eligibility:

All Genders

18-80 years

Phase:

NA

Brief Summary

The first questions asked by patients with a new diagnosis of Amyotrophic Lateral Sclerosis (ALS) often include: "Does exercise help slow the progression of the disease?", "Is there any harm in exerci...

Eligibility Criteria

Inclusion

  • Participants with familial or sporadic ALS diagnosed as possible, laboratory-supported probable, probable, or definite according to the WFN El Escorial criteria
  • Participants who are ages 18-80, inclusive.
  • Slow Vital Capacity (SVC) must be equal to or greater than 70% of predicted value
  • ALSFRS-R score \>30.
  • Patients who are currently on any medications must be on a stable dose for the past 30 days.
  • Participants must provide informed consent prior to completion of any study procedures.

Exclusion

  • Participants who are already performing \>30 min. of endurance exercise/day for ≥ 3x/week (Borg scale-- "hard" or "somewhat hard") within 30 days of screening.
  • Participants who are already performing resistance exercise ≥ 3x/week within 30 days of screening.
  • Neurologic
  • Participants with history of ALS symptoms over 5 years duration
  • Inability to obtain consent (psychiatric or dementing illness)
  • History of neuromuscular dysfunction not related to ALS
  • Cardiac
  • Patents with clinically significant ECG abnormalities
  • Uncontrolled hypertension (SBP\>160 or DBP\>110)
  • Recent history of angina (within the last 2 years)
  • Recent history of abnormal stress test (within the last 2 years)
  • Symptomatic severe aortic stenosis
  • Active endocarditis
  • Symptomatic heart failure
  • Respiratory
  • Subjects with a history of respiratory dysfunction not related to ALS (i.e. COPD)
  • General
  • Subjects with chronic infectious disease including HIV, hepatitis B or C.
  • History of substance abuse within the past year
  • Patients who have a history of poor compliance to medical regimens or study requirements.
  • Uncontrolled diabetes
  • Recent embolism (within the last 6 months)
  • Severe orthopedic conditions that would prohibit exercise
  • Pregnancy
  • Female subjects who are pregnant or planning to become pregnant.
  • Female subjects of childbearing potential who are not practicing contraception.

Key Trial Info

Start Date :

January 1 2012

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 1 2016

Estimated Enrollment :

60 Patients enrolled

Trial Details

Trial ID

NCT01521728

Start Date

January 1 2012

End Date

February 1 2016

Last Update

April 19 2016

Active Locations (4)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (4 locations)

1

Cedars-Sinai Medical Center

Los Angeles, California, United States, 90048

2

Johns Hopkins University

Baltimore, Maryland, United States, 21287

3

Massachusetts General Hospital

Charlestown, Massachusetts, United States, 02129

4

Carolinas Medical Center

Charlotte, North Carolina, United States, 28207